View
217
Download
0
Category
Preview:
Citation preview
Future TechnologiesDivision
2 0 1 0
2 0 1 5
2 0 2 0
www.zt-consulting.de
Future Technologies Division
Dr. Wolfgang Luther
Results of the European "NANOSAFE“-Project
page 2 / www.zt-consulting.de
Future Technologies Division
• Starting point and facts on the project
• Aspects of Risk Assessment and Management
• Results
• Conclusion
• Outlook
Outline
page 3 / www.zt-consulting.de
Future Technologies Division
Starting point of the project (2003)
InformationGap
Demand for a realisticrisk assessment andopen communication
• Many information on products/processes kept confidential
• Information available is widely spread throughout literature
• Understanding needs knowledge from a variety of disciplines (toxicology, chemistry, physics, epidemiology, law etc.)
Nanotech-Companies• Concerned with HSE apects
• Risks for workers, customersor future business?
Governments• Regulatory framework for NT
• Misdirected Nanotechinvestments ?
? ??Public/ Media• Increasing reporting on nano-risks
• Nano-Moratorium ?
page 4 / www.zt-consulting.de
Future Technologies Division
Lack of Data for Risk AssessmentEmission paths and volume
• Broad range of potential applications• Confidentiality of production processes and products• Particle release during use and disposal
Effects in human body/environment• Toxicological mechanisms• Entry, deaggregation and distribution in the human body • Transport, persistence and acumulation in the environment
Measurement techniques• Workplace measurement, biological samples• Relevant metrics for risk assessment & determination• Standardization
Potential
Risks ?
?
?
?
Risk Management• Personal protective measures for workers• Regulatory framework (chemicals, air quality, cosmetics, food, drugs)
page 5 / www.zt-consulting.de
Future Technologies Division
Nanosafe project - Some Facts
• Official Title: „Risk Assessment in Production and Use of Nanoparticles
with Development of Preventive Measures and Practice Codes“
• Funded by the European Commission within the Competitive and Sustain-
able Growth (GROWTH) programme of the 5th framework programme
• International interdisciplinary consortium of experts
• Duration of the Project: April 2003 to July 2004 (15 months)
• Methods: data base searches, literature analysis and interviews
page 6 / www.zt-consulting.de
Future Technologies Division
Project Partners
Co-ordinator:Nanogate Technologies GmbH, NT (D)
Contractors:• Commissariat a L'Energie Atomique, CEA (F)• VTT Technical Research Centre of Finland (FIN)• University of Oxford, Department of Engineering Science, (UK)• Oxonica Limited, Oxford (UK)• Jozef Stefan Institute, (Sl)• Katholieke Universiteit Leuven (B)• GSF-Forschungszentrum für Umwelt und Gesundheit GmbH, (D)• VDI Technologiezentrum GmbH, VDI-TZ (D)
page 7 / www.zt-consulting.de
Future Technologies Division
Particle Characteristics• Aspect-ratio• Diameter (particle/aggregate)• Surface area/ properties• Water solubility• Chemical composition
Emission• Production volume• Potential particle release (production, use, disposal)
Health effects• Humans• Experimental animals
Environmental effects• Persistence• Biomagnification• Long range transport
1 Hazard Identification 2 Hazard CharacterizationEpidemiological Studies• Workers• Consumers• Exposed population
In vivo studies• acute/chronic• different species
In vitro studies• Human/ animal, different cell types• Models (lung, skin, systemic)
Exposure routes• Inhalation, dermal, ingestion
Environmental monitoring• Biological uptake ...
Occupational monitoring• Personal exposure
3 Exposure Assessment
4 Risk CalculationSusceptibility extrapolation models• high dose low dose• animal human
Threshold value calculation• Intake, immission conc., maximum workplace conc.
6 Risk ManagementPreventive Measures• Personal protection equip.• Modification of processes
Regulation• Exposure/ immission stand. • Production restrictions
6 Steps of Risk Assessment and Management
5 Risk Communication
Regulatory bodies, industry
Science, Public, Consumers
page 8 / www.zt-consulting.de
Future Technologies Division
Working Groups
• WG 1: Types of nanomaterials, manufacturing and handling procedures Group Leader: VTT, Pertti Lintunen
• WG 2: Applications, industrial and consumer Group Leader: NT, Ulrike Dellwo
• WG 3: Potential particle release, circumstances and conditions Group Leader: CEA, Frédéric Schuster
• WG 4: Danger to health, reaction mechanism with human organism Group Leader: KUL, Peter Hoet
• WG 5: Recommended preventive measures Group Leader: GSF, Irene Brueske-Hohlfeld
• WG 6: Standards and regulatory recommendations Group Leader: VDI-TZ, Wolfgang Luther
page 9 / www.zt-consulting.de
Future Technologies Division
ResultsTypes of nanomaterials and manufacturing
Dispersion in• gases (aerosols)• liquids (e.g. gels, ferrofluids)• solids (e.g. matrix materials)
Shape/Structure• spheres• needles, tubes• platelets
NanoparticulateMaterials
UltrafineAerosols
Quantumdots
Nano-particles
Nano-tubes
Nano-capsules
Origin• natural• unintentionally released• manufactured („old“, „new“)
Aggregation state• single particles• aggregates• agglomerates
Surface modification• untreated • coated • core/shell particles
Manufacturing• gas phase• liquid phase • mechanical procedures
Chem. composition• metals/ metal oxides• polymers, carbon• biomolecules
page 10 / www.zt-consulting.de
Future Technologies Division
ResultsApplications
Form of Application• Fixed in a solid matrix• Dispersed in liquids, slurries ... • Dry powders• Closed systems• Open application ...
Types of Products• Intermediates
– Fillers, coatings ...• End user products
– electronics, medicine,
food, cosmetics ...
Production Volume• laboratory scale (< 1 t p.a. quantum dots)• semitechnical-scale (CNT)• Industrial scale (> KT p.a. carbon black, aerosil, titania...)
page 11 / www.zt-consulting.de
Future Technologies Division
ResultsExposure to Nanoparticles
Source: Royal Society
WorkersTake in mind: Exposure from con-ventional processes:• Smelting, soldering• Dusts and sprays
Consumers• Cosmetics, Drugs
Take in mind: Exposure of popula-tion from unintentio-nally released nano-particles and natural aerosols• Diesel exhaust !
page 12 / www.zt-consulting.de
Future Technologies Division
ResultsPotential Particle Release during Manufacturing
• Most of processes in an inert atmosphere or in vacuum, relatively safe except in case on unexpected failures during the processing (e.g.chamber failures causing leakages).
• Leakages are risk especially at high pressure conditions (e.g. supercritical fluids)
• Collecting apparatus of nanoparticles must be able to stop the particles efficiently (filters, electrostatic devices, substrate plates, suspensions)
• Particle release is more likely to happen after the production process
– During handling, treatment or bagging of nanoparticles
– During cleaning procedures of the equipment
Source: CEA
In most cases:
Aggregates of
nanoparticles
page 13 / www.zt-consulting.de
Future Technologies Division
ResultsPotential Entry Routes into the Human Body
Source: Encarta Enzyklopädie Standard 2003, Microsoft Corporation
Potential Health Effects• Lung: Inhalation of solid (poorly soluble)
material– Biopersistence & Cancer risk– Systemic translocation of particles– Thrombosis and lung inflammation
• Intestinal tract: No evidence for uptake of
nanoparticles, except drugs
• Skin:– Translocation of particles from topical exposure– Mechanical skin irritation
page 14 / www.zt-consulting.de
Future Technologies Division
Particles in the nanosize range can certainly enter the human body via the lungs
and the intestines; penetration via the skin is less evident although strong evidence
exists that some known particles can penetrate deep into the dermis.
The penetration is depending on the size and surface properties of the particles
and also depends on the point of contact in the lung, intestines or skin
The distribution in the body is strongly depending on the surface characteristics of
the particle.
There is no universal ”nanoparticle” to fit all the cases, each nanomaterial should
be treated individually when health risks are expected.
The health risks of inhaled fibrous material needs to be examined with care,
because it is general accepted that fibres that are not cleared easily from the lungs
can induce pulmonary disease.
ResultsToxicological Assessment
page 15 / www.zt-consulting.de
Future Technologies Division
ResultsPreventive Measures for workers
• Process modification
• Isolation of process
• Local exhaust ventilation
• Work practices
• Personal protective
equipment (respirators,
masks, gloves ...)
• Safety data sheets
page 16 / www.zt-consulting.de
Future Technologies Division
• Immission Control
• Chemicals
• Labor protection
• Pharmaceutical and medicine
• Food, consumer goods and cosmetics
• Novel-Food
ResultsLegislation Framework - Areas to be Considered
page 17 / www.zt-consulting.de
Future Technologies Division
Area of interest Regulation and Safety Measures
Drugs Drug Approval Application ProcessFood Impose Conditions for manufacturing processeses
Obligations for indication and permission of producing and selling Prohibitions labelling and warning notices
Consumerproducts andcosmetics
Product safety standards Establish obligations for the indication and permission of
producing and selling
Air pollution Limit values for emission and immission
Worker Safety Exposure limits Safety standards and guidelines
Hazardoussubstances andchemicals
Registration of substances/chemicals (e.g. CAS) Guidelines for handling of hazardous substances
ResultsOptional regulation measures
page 18 / www.zt-consulting.de
Future Technologies Division
ResultsRegulation Activities
Worker Safety • Regulation relies on limit values for hazardous chemicals (e.g. WHO or MAK)
• dependent on the availability of measurement techniques, existing standards for based on mass concentrations, not applicable to ultrafine aerosols
Consumer Protection • So far no regulations for nanoparticle exist or are planned for the near future,
• Material producers will be responsible for the assessment of health risks associated with their products
Chemical Legislation • Also in the frame of chemical legislation particle size does not play a role for the registration of new substances
• European Chemical Policy (Reach) will already create bottleneck of assessing
30000 „old“ substances Urgent need for preliminay risk assessment scheme to prioritize work
page 19 / www.zt-consulting.de
Future Technologies Division
Productionvolume• < 10 kg• < 1 t p.a.
ToxicologicalScreeningLung toxicitySystemic effectsOxidative stressorEndocrine disruptorSensitiser/Adjuvant
EcotoxicologicalScreeningPersistenceLong rangeTransportationBiomagnification
Scheme for Preliminary Risk Assessment ofNanoparticles
Aerosolrelease ProductionHandlingProcessing
Directexposure CustomersWorkersEnvironment
ParticlepropertiesSolubilityAspect RatioDiameterSurface
Increasing investigation expenditures
Intermediate priorityLow priority High priority
Find suitable parameters for prioritize investigations !
page 20 / www.zt-consulting.de
Future Technologies Division
• R&D-Projects and Data Collection (Development of methods and screening tests, data collection on workplace exposure and nanoparticle behaviour in the human body and the environment)
• Minimizing risks (protection equipment, process modification)
• International Standardisation (methods, guidelines, etc.)
• International cooperation and initiatives
• Regulation should be considered on basis of existing legislation
• Risk Communication (two-way process)
Some General Recommendations
page 21 / www.zt-consulting.de
Future Technologies Division
• Several Research Projects are going to start soon in Germany (Nanocare), Europe (Nanosafe II) and the U.S.
• Nanotechnology is on the agenda of standardization and regulation bodies
• Generate more data as a basis for a matter of fact oriented discussion
Outlook
Recommended